Pilot Trial Evaluating Patient Experience With the MemorEM for Patients With Neurological Diseases
Launched by NEUROEM THERAPEUTICS, INC. · Jun 30, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how patients with neurological conditions, like Alzheimer’s disease, Parkinson’s disease, and other similar brain disorders, feel about using a device called MemorEM. This device is worn on the head and is designed to help with these conditions. The main goal is to hear directly from patients and their caregivers about their experiences with the device—what they like, what could be better, and how easy it is to use. This feedback will help improve the device and make it easier for patients to use in the future. The study also looks at whether the device might help with other neurological diseases beyond Alzheimer’s.
People who have been diagnosed with neurological diseases involving abnormal protein build-up in the brain and who have a caregiver to help manage their treatment may be eligible to join. Participants will continue their usual medical care and simply use the MemorEM device as they choose, possibly for up to two years. They will share short updates about their experience with the device and suggest any improvements. The device has been found to be safe in earlier studies. However, people with certain health conditions, like uncontrolled seizures, serious heart problems, or metal implants in the head (other than dental implants), may not be able to participate. Overall, this trial focuses on understanding the patient’s perspective to help make the MemorEM device better and more useful in treating neurological diseases.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient diagnosed with a neurological disease involving aggregated proteins such as Alzheimer's and its variants, Parkinson's, Frontotemporal dementia, Amyotrophic lateral sclerosis, Tauopathies, and other related neurological diseases.
- • Presence of a caregiver(s) responsible for ensuring treatment compliance and potentially with authority to make medical decisions for the patient if the patient is not competent to make those decisions
- • Willing to sign NeuroEM's patient consent form
- Exclusion Criteria:
- • Patient has uncontrolled: Seizures, Epilepsy, Depression, Bipolar disorder, psychotic disorders, alcoholism or drug addiction
- • Presence of metal implants in the head, except for metal dental implants
- • Patient has hypertension that is unresponsive to anti-hypertensive medications
- • Patient has implanted medication pumps unless cleared by physician
- • Patient has significant heart disease, as determined by a physician
About Neuroem Therapeutics, Inc.
Neuroem Therapeutics, Inc. is a pioneering biopharmaceutical company dedicated to advancing innovative therapies for neurodegenerative diseases. Focused on the development of novel treatment modalities, Neuroem harnesses cutting-edge research and technology to address unmet medical needs in areas such as Alzheimer's disease and other cognitive disorders. With a commitment to improving patient outcomes, the company collaborates with leading academic institutions and industry partners to drive clinical trials and bring transformative solutions to market. Neuroem Therapeutics is at the forefront of neurotherapeutics, aiming to enhance the quality of life for patients and their families through effective, targeted interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported